Amgen
 |
|
| Type | Public |
|---|---|
| Traded as | NASDAQ: AMGN NASDAQ-100 Component S&P 500 Component |
| Industry | Biotechnology |
| Founded | 1980 |
| Headquarters | Thousand Oaks, California, U.S. |
| Key people | Kevin W. Sharer (Chairman and CEO) Robert A. Bradway (President and COO) |
| Products | Epogen, Aranesp, Kineret, Enbrel, Neulasta, Neupogen, Nplate, Vectibix, Prolia, XGEVA and Sensipar/Mimpara. |
| Revenue |  US$ 15.053 billion (2010)[1] |
| Operating income | US$ 5.545 billion (2010)[1] |
| Net income | US$ 4.627 billion (2010)[1] |
| Total assets | US$ 43.486 billion (2010)[1] |
| Total equity | US$ 23.294 billion (2010)[1] |
| Employees | 17,400 (December 2010)[1] |
| Website | Amgen.com |
Amgen Inc. (NASDAQ: AMGN, SEHK: 4332) is an international biotechnology company headquartered in Thousand Oaks, California. Located in the Conejo Valley, Amgen is the world's largest independent biotech firm. The company employs approximately 17,000 staff members. Its products include Epogen, Aranesp, Enbrel, Kineret, Neulasta, Neupogen, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA. Epogen and Neupogen (the company's first products on the market) were the two most successful biopharmaceutical products at the time of their respective releases.
BusinessWeek ranked Amgen first on the S&P 500 for being one of the most "future-oriented" of those five hundred corporations.[2] BusinessWeek ostensibly calculated the ratio of research and development spending, combined with capital spending, to total outlays; Amgen had the fourth highest ratio, at 506:1000.
Amgen has several collaborative arrangement with Pfilzer Inc, GlaxoSmithKline plc., Takeda Pharmaceutical Company limited, Kyowa Hakko Kirin Co. Ltd., Daiichi Sankyo and Array BioPharma Inc..
Amgen is the largest employer in Thousand Oaks and second only to the United States Navy in terms of number of people employed in Ventura County.
With plans to expand into market.[3]
It is a leading member of the U.S. Global Leadership Coalition, a coalition of over 400 companies and NGOs that promotes increased funding for US diplomatic and international development programs.[4]
In 2010, Amgen began sponsoring the Tour of California, one of only three major Union Cycliste Internationale events in the United States.
Contents |
[edit] History
The word AMGen is a portmanteau of the company's original name, Applied Molecular Genetics, which became the official name of the company in 1983 (three years after incorporation and coincident with its initial public offering). The company's first chief executive officer, from 1980, was George B. Rathmann, followed by Gordon M. Binder in 1988, followed by Kevin W. Sharer in 2000. The company has made at least five major corporate acquisitions.
[edit] Acquisition history
- 1994 - Synergen, Inc.
- 2000 - Kinetix Pharmaceuticals, Inc.
- 2002 - Immunex Corporation[5]
- 2004 - Tularik, Inc.
- 2006 - Abgenix, Inc.[6]
- 2006 - Avidia, Inc.
- 2007 - Ilypsa, Inc.
- 2007 - Alantos Pharmaceuticals Holdings, Inc.
- 2011 - BioVex Group, Inc.
- 2012 - Micromet, Inc.
[edit] Products
As of August 9, 2011, Amgen had twelve approved drugs or therapeutic biologicals for seventeen conditions (conditions lists are highly generalized; see each article for more detail):
- Aranesp (darbepoetin alfa) (for anemia)
- Enbrel (Etanercept) (for various forms of arthritis)
- Epogen (Epoetin) (also known as Procrit; for anemia)
- Kepivance (Palifermin) (for oral mucositis)
- Kineret (Anakinra) (for rheumatoid arthritis)
- Neupogen (Granulocyte-Colony Stimulating Factor) (for neutropenia)
- Neulasta (PEG Granulocyte-Colony Stimulating Factor or "Pegfilgrastim") (for neutropenia)
- Vectibix (Panitumumab) (for colon cancer)
- Sensipar/Mimpara (Cinacalcet) (for Primary & Secondary hyperparathyroidism, a mineral metabolism complication common in patients with kidney failure)
- Nplate (Romiplostim) (for chronic immune thrombocytopenic purpura)
- Prolia (denosumab) (for postmenopausal osteoporosis)
- XGEVA (denosumab) (for the prevention of skeletal-related events (SREs) (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumors)
In other drug discovery phases (Phases I, II, III and in preclinical development), the company has twenty-three pharmacologic agents for twenty-eight conditions; nineteen of the candidates are not currently approved for any indication.
[edit] See also
- Kirin-Amgen v Hoechst Marion Roussel, a UK patent case decided by the House of Lords
[edit] References
- ^ a b c d e f "2010 Form 10-K, Amgen Inc.". U.S. Securities and Exchange Commission. http://www.sec.gov/Archives/edgar/data/318154/000095012311018800/v57113e10vk.htm.
- ^ Coy, Peter (2004-10-11). "The Search for Tomorrow". BusinessWeek. http://www.businessweek.com/@@UPQMFoUQ96PcERwA/magazine/content/04_41/b3903476.htm. access to article requires free registration on site
- ^ Dineen, J.K.; Leuty, Ron (August 12, 2007). "Amgen Slows its Bay Area Expansion". San Francisco Business Times web site. http://www.bizjournals.com/sanfrancisco/stories/2007/08/13/story1.html. Retrieved August 14, 2007.
- ^ http://www.usglc.org/about/our-coalition
- ^ Amgen Completes Acquisition Of IMMUNEX
- ^ Amgen Completes Acquisition of Abgenix; Acquisition Provides Amgen with Full Ownership of Panitumumab and Eliminates a Denosumab Royalty
[edit] External links
- Official website
- Company Profile at Pharmaceutical Business Review
- Amgen Inc. Company Profile Profile at Google Finance.
- Businessweek.com
|
|||||
